Header

Multiple Myeloma Clinical Trials

Category:Adult
Status:Active

Displaying all 23 trials

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is curre...

Diagnosis: Multiple Myeloma

Phase: 3

Protocol Number: 10-106

Phase 2b Open-Label Single-Arm Study of Selinexor & Dexamethasone in Patients Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide

Patients with heavily pretreated, quad-exposed multiple myeloma (refractory to one PI and one IMiD) will receive selinexor 80 mg (45 mg/m2 BSA) plus low-dose dexamethasone (20 mg), both twice weekly.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-291

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Control...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-358

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-491

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidom...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-475

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide m...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-113

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 15-571

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide expo...

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-199

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

Diagnosis: Multiple Myeloma

Phase: 2

Protocol Number: 16-313

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma

Diagnosis: Multiple Myeloma

Phase: 1 / 2

Protocol Number: 15-519

ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma

It is possible that the combination of lenalidomide, dexamethasone and ACE 011 may reduce or prevent the growth of cancer cells along with improving anemia and bone lesions that sometimes occur in ...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 11-318

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-termina...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 13-348

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal...

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 13-581

Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Diagnosis: Multiple Myeloma

Phase: 1

Protocol Number: 16-054

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory Multiple Myeloma (rrMM),...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 14-201

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 15-446

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residu...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 15-407

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 15-522

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Dir...

Diagnosis: Solid Tumor/Phase I, Multiple Myeloma, Lymphoma

Phase:

Protocol Number: 16-406

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1 will be an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma. Phase 2b will b...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-427

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: - Trametinib - Dabrafenib

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-352

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete res...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 16-589

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Primary Objective: To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalid...

Diagnosis: Multiple Myeloma

Phase:

Protocol Number: 17-059

'